AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01454-07v1
52/5/1837    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Faúndez, M.
Right arrow Articles by Maya, J. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faúndez, M.
Right arrow Articles by Maya, J. D.
Antimicrobial Agents and Chemotherapy, May 2008, p. 1837-1839, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01454-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Buthionine Sulfoximine Has Anti-Trypanosoma cruzi Activity in a Murine Model of Acute Chagas' Disease and Enhances the Efficacy of Nifurtimox{triangledown}

Mario Faúndez,1,3 Rodrigo López-Muñoz,1 Gloria Torres,1 Antonio Morello,1 Jorge Ferreira,1 Ulrike Kemmerling,2 Myriam Orellana,1 and Juan D. Maya1*

Program of Molecular and Clinical Pharmacology, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile,1 Program of Anatomy and Developmental Biology, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile,2 Facultad de Farmacia, Universidad de Valparaíso, Valparaíso, Chile3

Received 8 November 2007/ Returned for modification 15 December 2007/ Accepted 6 February 2008

L-Buthionine (S,R)-sulfoximine (BSO) at a dose of 220 mg/kg of body weight/day showed an anti-Trypanosoma cruzi effect in infected mice, increasing their survival rate and decreasing the parasitemias and parasite burden in the hearts. Treatment with BSO plus nifurtimox caused an increase in the survival rate in comparison to the rates with treatment with each drug alone.

* Corresponding author. Mailing address: University of Chile, Faculty of Medicine, Molecular and Clinical Pharmacology Program, P.O. Box 70000, Santiago 7, Chile. Phone: (562) 9786071. Fax: (562) 7355580. E-mail: jmaya{at}med.uchile.cl

{triangledown} Published ahead of print on 10 March 2008.

Antimicrobial Agents and Chemotherapy, May 2008, p. 1837-1839, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01454-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.